Two-step control mechanism identified in mouse stem cells
Scientists identified two distinct control mechanisms in the developmental transition of undifferentiated stem cells into healthy brain cells. This fundamental research using mice may inform regenerative medicine treatments for neurodegenerative diseases and spinal cord injuries, in the future.
When an embryo develops, stem cells differentiate into all the types of cells that the adult will need. Neural stem cells differentiate first into neurons, or nerve cells, and then into astrocytes, support cells in the brain. Neural stem cells lose their potential to produce neurons as the embryo matures.
Professor Yukiko Gotoh at the University of Tokyo leads the team of scientists who identified the epigenetic control mechanisms of how neural stem cells lose the potential to produce neurons.
“It is a paradox for regenerative medicine that neural stem cells produce fewer cells as they differentiate into additional cell types. We would like to grow specific cell types and lots of them,” said Gotoh.
All body cells have the same DNA, but different genes are turned on or off to make different cell types. To understand brain development, researchers examined how a protein called polycomb repressive complex 1 (PRC1) controls the expression of genes related to neuronal function inside neural stem cells. Earlier results had revealed PRC1 regulates gene expression in stem cells, but not the specifics how and when.
They collected neural stem cells from the brains of mouse embryos that grew inside a mother mouse until the midpoint of the embryonic development period, or 11 days after conception. Then, researchers separated the cells into two groups to grow outside the body for different periods: one group until it reached the early stage of neural development, when neurons are formed, and the other group until the late stage when the cells turn into astrocytes.
“Neural stem cells must keep track of their own calendar. Even while growing outside the body they differentiate normally into neurons and then into astrocytes,” said Gotoh.
Researchers discovered that PRC1 represses genes related to neuronal function through activity of adding a molecule called ubiquitin during early stages of brain development in which neural stem cells produce neurons. Then, at later stages of brain development when stem cells switch to producing astrocytes, the ubiquitin-adding activity becomes unnecessary. PRC1 instead becomes clusters (polymers) on these genes in the late stage.
PRC1 represses genes related to neuronal function transiently in the early stage, but permanently in the late stage of brain development.
Understanding the different control mechanisms at two distinct stages of brain development may provide researchers with new tools to manipulate neural stem cells. The results may also help develop methods to change a cell’s type: for example, collecting astrocytes out of adult patients and turning those cells into new neurons.
Understanding how the brain first develops different cell types helps researchers imagine how to design treatments for neurodegenerative conditions, such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), when those cells are damaged. Scientists could also use the same information to treat neuron damage elsewhere in the body, including spinal cord injuries and other ailments.